GELS

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

Dollar change -0.05
Percentage change -2.18	%

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-	Insider Own	60.36%	Shs Outstand	9.44M	Perf Week	1.82%
Market Cap	21.15M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	3.74M	Perf Month	-7.82%
Income	-	PEG	-	EPS next Q	-	Inst Own	-	Short Float	0.03%	Perf Quarter	-10.40%
Sales	-	P/S	-	EPS this Y	-	Inst Trans	0.00%	Short Ratio	0.00	Perf Half Y	-
Book/sh	1.07	P/B	2.09	EPS next Y	-	ROA	-	Short Interest	0.00M	Perf Year	-
Cash/sh	0.00	P/C	1057.28	EPS next 5Y	-	ROE	-	52W Range	1.42 - 5.50	Perf YTD	-3.45%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-59.27%	Beta	-
Dividend TTM	-	Quick Ratio	0.08	Sales past 5Y	-74.90%	Gross Margin	-	52W Low	57.75%	ATR (14)	0.33
Dividend Ex-Date	-	Current Ratio	0.08	EPS Y/Y TTM	-	Oper. Margin	-	RSI (14)	45.32	Volatility	6.56% 13.80%
Employees	20	Debt/Eq	0.25	Sales Y/Y TTM	-	Profit Margin	-	Recom	-	Target Price	-
Option/Short	No / Yes	LT Debt/Eq	0.12	EPS Q/Q	-	Payout	-	Rel Volume	0.08	Prev Close	2.29
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-	Earnings	-	Avg Volume	511.78K	Price	2.24
SMA20	-5.35%	SMA50	-11.96%	SMA200	-7.26%	Trades		Volume	39,424	Change	-2.18%

Feb-04-25 08:00AM	Gelteq Launches SportsGel Brand and Signs Distribution Agreement with E-Commerce Solutions Company in Asia-Pacific Region, WPIC (GlobeNewswire)
Jan-24-25 08:00AM	Gelteq Appoints Matthew Jones as Head of Sports Performance (GlobeNewswire)
Dec-19-24 08:30AM	Gelteq Appoints Dr. Paul Wynne as Chief Scientific Officer to Propel Innovative Ingestible Gel Technology (GlobeNewswire) +21.97%
Dec-17-24 08:30AM	Gelteq Receives FDA Approval of its Suitability Petition for New Animal Drug (GlobeNewswire) +5.79%
Dec-09-24 08:30AM	Gelteq to Participate in the Benchmark Company 13th Annual Discovery Investor Conference (GlobeNewswire) +78.00%
08:30AM	Loading…
Dec-02-24 08:30AM	Gelteq Announces Largest U.S. Customer Increases Initial Order by 50% to Meet Growing Market Demand (GlobeNewswire) +91.02%
Nov-26-24 08:30AM	Gelteq Announces 400,000 Units Enter into Production in November 2024 (GlobeNewswire)
Nov-12-24 09:00AM	Gelteq Expands Operations in United States with Appointment of Adam Bendell as President of U.S. Operations to Scale Domestic Business (GlobeNewswire)
Oct-30-24 10:00AM	Gelteq Limited Closes US$5.2 Million Initial Public Offering (GlobeNewswire) -19.40%
Oct-28-24 09:50PM	Gelteq Limited Prices US$5.2 Million Initial Public Offering (GlobeNewswire)

Gelteq Ltd. is a biotechnology company. It focuses on the development and commercialization of white label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care, and other products. The firm also offers edible gels. The company was founded by Nathan J. Givoni and Simon H. Szewach on October 15, 2018 and is headquartered in Melbourne, Australia.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Gelteq Ltd

Upgrade your FINVIZ experience